Growth hormone (GH) supplementation may help to preserve erectile function. We assessed whether serum insulin-like growth factor 1 (IGF-1) levels, a surrogate for GH levels, correlate with sexual function scores in 65 men who completed the Sexual Health Inventory for Men (SHIM) and Expanded Prostate Cancer Index Composite (EPIC) questionnaires, and had serum IGF-1 and testosterone levels determined. Median±s.d. IGF-1 level, SHIM and EPIC scores were 235.0±86.4, 19.5 ± 8.7 and 56.4 ± 28.3 mg ml
Introduction
The male sexual cycle is regulated by a complex interplay between neuroendocrine, vascular and genital systems, and dysregulation of these systems can result in erectile dysfunction. The contributions of both vascular insufficiency and genital microstructural abnormalities to erectile dysfunction have been extensively studied, while the neuroendocrine axes have only recently come under scrutiny in the setting of male sexual function. 1, 2 The aging process is associated with a decline in serum testosterone levels, which when present together with symptoms of androgen deficiency is termed late-onset hypogonadism (LOH). 3 The true prevalence of LOH remains uncertain, although a recent report suggests that LOH is present in 3.1-7.0% of men less than 70 years old, and up to 18.4% of men over the age of 70, when using total testosterone levels o300 ng dl
À1
and symptomatic hypogonadism as diagnostic criteria. 4 Testosterone replacement in men with LOH has been shown to ameliorate the symptoms of LOH and results in improvements in erectile function without significantly increasing the incidence of clinically significant prostate cancer, although the mechanism of this improvement in erectile function remains incompletely elucidated. 3, 5, 6 However, it does appear that this mechanism involves both local and central mechanisms. [7] [8] [9] [10] [11] [12] [13] Growth hormone (GH) levels, like testosterone, are also known to decline in an age-dependent manner.
14 This progressive decline has long been assumed to be physiological, although decline in GH secretion is associated with reduced lean body mass and bone density, an increased incidence of ischemic heart disease, dyslipidemia and erectile dysfunction, clinical outcomes that have also been observed in LOH. [15] [16] [17] [18] [19] [20] [21] An association between low GH levels and erectile dysfunction has been described in otherwise healthy male subjects, and recent in vitro and animal studies suggest that GH upregulates nitric oxide (NO) and may thus help to maintain erectile function. 20, [22] [23] [24] The downstream effects of growth hormone are thought to be mediated in part by insulin-like growth factors 1 and 2 (IGF-1,-2), secretion of which is upregulated by GH. Given that the half-life of IGF-1 (12-15 h) is significantly longer than that of GH (less than 20 min), IGF-1 is considered to be a superior serum marker of growth hormone secretion and activity and is therefore used as a surrogate marker for GH levels, and has been validated as an accurate marker of GH levels over time. 25 Studies have shown that GH and testosterone levels are closely related and that boys with delayed puberty and healthy older men with low-normal testosterone and IGF-1 have increased serum GH and IGF-1 levels with exogenous testosterone treatment.
2,26 IGF-1/GH and testosterone also appear to have similar clinical effects, with IGF-1/GH reversing endothelial progenitor cell dysfunction and testosterone increasing the number of endothelial progenitor cells. 27, 28 Thus, it is reasonable to expect that low GH levels will correlate with sexual dysfunction, and a link between GH levels and male sexual dysfunction has been demonstrated. 20, 29 This study builds on the current literature and examines a relationship between IGF-1 and validated measures of patientreported sexual function, namely the Sexual Health Inventory for Men (SHIM) and the Expanded Prostate Cancer Index Composite (EPIC) questionnaires.
30,31

Methods
Patient enrollment
The retrospective study protocol was approved by the Institutional Review Board of Baylor College of Medicine and 65 patients scheduled for radical prostatectomy between July 2007 and June 2008 from the practice of MK and LIL were included in the study. All subjects provided a preoperative blood sample for serum IGF-1 and testosterone levels between 1 week and 2 months before scheduled prostatectomy, and all samples were analyzed in the same laboratory (Baylor College of Medicine Department of Nuclear Medicine) using enzyme-linked immunosorbent assay in keeping with national standards for reproducibility and accuracy. Subjects were asked to complete the SHIM questionnaire as well as the sexual function domain portion of the EPIC questionnaires before prostatectomy. None of the subjects included in the study were treated with hormone ablation therapy for prostate cancer before or after completion of the above questionnaires.
Statistical analysis
Statistical analysis of the data was performed using Statistical Package for the Social Sciences (SPSS), version 7.5, for Windows (Chicago, IL, USA) and Stata IE Version 10 for Macintosh (College Station, TX, USA). The distribution of data was determined using histogram analysis. Multivariate analysis was carried out using linear regression analysis. Spearman's correlation coefficients were calculated and P-values o0.05 were considered statistically significant.
Results
The median age of subjects included in the study was 58 years (range, 46-77 years) ( Table 1) . Associated comorbid conditions included hypertension (41.5% of patients), hyperlipidemia (46.2%), vasculopathy (4%), as defined by symptoms or objective measurements of coronary artery disease, carotid stenosis or peripheral vascular disease and diabetes IGF-1 levels correlate with sexual dysfunction AW Pastuszak et al mellitus with (14%) or without (0%) insulin dependence. Other concomitant conditions included current cigarette smoking (3%), a history of cigarette smoking (21%), occasional to moderate alcohol consumption (49%), depression (6%), erectile dysfunction before radical prostatectomy (29%) and testosterone replacement therapy before radical prostatectomy (3%). The most common Gleason score was 3 þ 3 in 33 of 58 patients with pathology results available (Gleason score range 3 þ 3 to 4 þ 5).
To assess whether validated questionnaires for self-reporting of sexual function correlate with IGF-1 levels, serum IGF-1 levels were correlated with SHIM questionnaire scores. The median ± s.d. serum IGF-1 level across the subject pool was 235.0± 86.4 ng dl À1 (range 87-506 ng dl À1 ) ( Table 1 ). The median ± s.d. SHIM questionnaire score was 19.0 ± 8.7 (range 1-25). After the data distribution had been determined to be non-parametric using histogram analysis, Spearman's rank correlation coefficients were calculated between IGF-1 and SHIM scores. There was a significant correlation between IGF-1 levels and total SHIM scores for all ages (r ¼ 0.31 P ¼ 0.02) (Table 2, Figure 1) . Notably, there was also a significant correlation between IGF-1 level and score for each individual SHIM question for all ages ( Table 2 , SHIM 1-SHIM 5). Stratification based on subject age demonstrated a significant correlation between IGF-1 level and SHIM score in men 470 years old for total SHIM score (r ¼ 0.89, P ¼ 0.04) and all individual questions (Table 2 ). In contrast, no significant correlation was demonstrated between IGF-1 level and total SHIM score for any other age group, although a correlation approaching statistical significance was observed in the 50-59-year-old age group for total SHIM score (r ¼ 0.32, P ¼ 0.08), a significant correlation was observed for the second SHIM question (SHIM 2, r ¼ 0.41, P ¼ 0.02) in this age group. Although it is unclear why no statistically significant correlation between questionnaire scores and IGF-1 levels in younger age groups is observed, there are no significant differences in IGF-1 levels between age groups, while EPIC and SHIM scores were relatively higher in younger men, which may affect the correlation between IGF-1 levels and questionnaire scores in these age groups. Taken together, these data suggest that the 470-year-old age group is the most sensitive demographic to assess using the SHIM questionnaire if aiming to determine whether sexual function is related to IGF-1 levels, although the SHIM score may also be predictive in other age groups based on the isolated finding in the 50-59-year-old group. In addition, we should also consider the possibility that the statistically significant differences observed in our subgroups could result simply from chance. Larger population studies may better clarify the age-specific utility of IGF-1 levels as a predictor of sexual function.
Subjects' IGF-1 levels were also correlated with self-reported sexual function as assessed using the sexual and hormonal domains of the EPIC questionnaire. The median ± s.d. score of the sexual domain of the EPIC questionnaire was 56.4±28.3 (range 6.3-96.2) ( Table 1 ). Similar to the findings with SHIM score, there was a significant correlation between the sexual domain of the EPIC questionnaire and IGF-1 levels for all ages (r ¼ 0.30, P ¼ 0.02) Figure 2 ). In contrast, there was no correlation between the sexual domain of the EPIC questionnaire and IGF-1 levels for any single age group, although the correlation within the 470-year-old age group approached significance (r ¼ 0.87, P ¼ 0.06). In addition, no significant correlation was found between testosterone level and SHIM or EPIC score, which supports previous findings in the literature. 32 In addition, there was no correlation between the hormonal domain of the EPIC questionnaire and either IGF-1 or testosterone levels.
To control for the impact of comorbidities on IGF-1 levels, multivariate analysis using linear regression modeling was carried out. These data demonstrated that only hyperlipidemia is predictive of IGF-1 levels (P ¼ 0.02, Table 3 ), with other comorbidities not significantly impacting IGF-1 levels. The prevalence of hyperlipidemia in our subject population as a function of age revealed no significant difference, suggesting that the presence of hyperlipidemia does not affect the findings described above.
In light of reports suggesting that elevated IGF-1 and GH levels stimulate prostate cancer cell growth, we determined the Spearman's rank correlation between IGF-1 level and both total Gleason score, as well as the high component of the Gleason score. Our data demonstrate no significant correlation between IGF-1 levels and Gleason score, suggesting that while GH and IGF-1 may stimulate the growth of prostate cancer, tumor severity is not affected in this group of men scheduled for radical prostatectomy. In addition, no correlation was shown between testosterone level and Gleason score for all ages or in any age group (data not shown).
Discussion
The prevalence of LOH is likely to continue increasing as the world's population ages. Recent work has established a role for testosterone in the development and maintenance of erections, and testosterone replacement has been shown to ameliorate the symptoms of LOH, including erectile dysfunction. [33] [34] [35] In contrast, the role of GH in the maintenance of sexual function is less well established, although studies have shown a relationship between GH and erectile function.
In this work, we demonstrate a statistically significant correlation between self-reported, validated measures of sexual function in men, the SHIM and EPIC questionnaires, and IGF-1 levels, most robustly in men 470, as well as in men between 50 and 59 years old. In contrast, a correlation between testosterone levels and SHIM/EPIC scores is not demonstrated. Notably, study subjects were given SHIM and EPIC questionnaires after a diagnosis of prostate cancer had been made. Given the psychologically stressful nature of a cancer diagnosis, this may have resulted in lower SHIM and EPIC scores. However, given that all men in the study carried the diagnosis of prostate cancer, a uniform reduction in questionnaire scores would be expected, a possibility we cannot evaluate given the lack of pre-diagnosis questionnaire responses. Erectile dysfunction is a known early predictor of coronary artery disease. Deficiency of GH or IGF-1 has been implicated in the pathogenesis of cardiovascular disease and atherosclerosis and is associated with an increased prevalence of ischemic heart disease. 16, 17 GH/IGF-1 deficiency is thought to contribute to endothelial dysfunction, and low GH/IGF-1 levels have been correlated with a decreased number and diminished function of endothelial progenitor cells, which function in vascular repair. 27 Notably, this endothelial progenitor cell dysfunction is reversible with GH administration, which suggests a possible role for GH in the treatment of vascular disorders, including erectile dysfunction. 27 GH and IGF-1 have also been shown to have antioxidant and anti-inflammatory effects in animal models, suggesting a protective role for GH/ IGF-1 in vascular disease given the role of oxidative stress in initiating lipid-lesion formation as well as in the destabilization and progression of these lesions. 36 Interestingly, our data link IGF-1 levels to hyperlipidemia, highlighting a potential interplay between serum lipids and GH/IGF-1 levels. Although it is tempting to hypothesize that this correlation may indicate a response by the GH axis to hyperlipidemia, additional analysis is necessary to fully elucidate this.
GH has been shown to modulate the NO/cyclic guanosine monophosphate signaling pathways and aid in the restoration of cavernosal smooth muscle integrity in rats. 24 GH levels increase during sexual arousal and GH has been shown to induce relaxation of smooth muscle in a dose-dependent manner and upregulate NO and cyclic guanosine monophosphate serum levels in human corpus cavernosum. 20, 29 GH has also been shown to have a trophic effect on neuronal and endothelial nitric oxide synthase-(nNOS and eNOS, respectively) containing neurons after cavernous neurotomy in rats, suggesting that GH may be important in the maintenance or restoration of erectile function post-prostatectomy. 23 Like, GH, IGF-1 has growthstimulating effects and is thought to improve erectile function in diabetic rats as measured by maximum intracavernosal pressure as well as the maximal intracavernosal pressure to mean arterial pressure ratio. 22, 37 Together these data support a role for GH and IGF-1 in sexual arousal and erectile function, and indicate that GH and IGF-1 may function using a well-established pathway for erectile stimulation.
A relationship between GH, IGF-1 and testosterone has previously been demonstrated. 1, 2 Curiously, no significant correlation is demonstrated between serum IGF-1 and testosterone levels or between testosterone levels and SHIM/EPIC scores in our work. However, we have observed this correlation to be lacking in patients seen in our practice that were not included in this study, and suspected that this finding may be related to the use of exogenous testosterone by patients before presentation to our clinic, which would affect serum testosterone levels and could affect the relationship between testosterone and IGF-1.
In light of our findings linking the GH axis to sexual dysfunction, it is conceivable that supplementation with GH or IGF-1 could improve recovery of erectile function after radical prostatectomy. However, there is concern regarding a possible role for GH, IGFs and IGF-binding proteins (IGFBPs) in the development of prostate cancer and stimulation of its growth. 26 GH has been shown to stimulate prostate cancer cell growth and both GH and the GH receptor is expressed in prostate cancer cells, suggesting a potential auto-or paracrine pathway for stimulating growth. 38 Elevated IGF-1 levels, as well as low IGFBP3 levels, were recently shown to correlate with an up to 21% increased risk of prostate cancer, and an increased risk of prostate cancer has been demonstrated in Latin men with elevated IGF-1 levels, results that have been echoed in other cohorts. [39] [40] [41] These data argue for caution when considering supplementation with GH or IGF-1 in men with erectile dysfunction.
In this study, we found no correlation between Gleason score and IGF-1 levels. Although this does not suggest that GH does not stimulate prostate cancer cell growth, the data argue that the GH axis does not stimulate development of more aggressive tumors. However, whether men being treated with GH have an increased risk of prostate cancer and whether exogenous GH administration affects tumor severity cannot be addressed. Further work defining the mechanisms of function of GH and IGF-1 in prostate cells should be undertaken and the risks of carcinogenesis should be more clearly defined. In addition to the lack of correlation between serum IGF-1 levels and Gleason score, no significant correlation was identified between serum testosterone levels and Gleason score. Although a link between serum testosterone levels and prostate cancer severity has been demonstrated, previous studies have focused on Gleason scores X8 and found an increased risk of more aggressive prostate cancer only in men X65 years old. 42 In our analysis, only four patients had Gleason score 8 or higher cancer and only one of these was more than 65 years old, which may explain a lack of correlation between serum testosterone level and Gleason score given the predominance of Gleason score 6 and 7 prostate cancer within our cohort. However, in a IGF-1 levels correlate with sexual dysfunction AW Pastuszak et al recent study of 478 men screened for prostate cancer with transrectal ultrasound-guided biopsy, no relationship was observed between serum testosterone level and prostate cancer severity. 43 Thus, it is possible that the relationship between testosterone level and Gleason score is indeed most significant in older men with more aggressive tumors.
Our study was limited by several factors. First, the study was performed with a cohort of men diagnosed with prostate cancer. Although the considerations for questionnaire score are addressed above, it is also possible that unaccounted for factors, including individual differences in anxiety levels before major surgery or as a result of the cancer diagnosis, may have affected both IGF-1 levels and erectile function. Second, most of the correlations, save for those in the 470-year-old age group, are fairly low. Although this could be a result of the factors above, there may be additional variables that affect the relationship between the GH axis and sexual function and are currently unaccounted for.
Considering the overlap between GH and testosterone in the pathogenesis of erectile dysfunction, it may be beneficial to evaluate both the testosterone and GH axes when evaluating etiology and considering the treatment of erectile dysfunction. Our results support a relationship between IGF-1 and male sexual function, and strengthen the argument to more closely study the role of IGF-1 in erectile dysfunction. There do not exist sufficient data to use IGF-1 or GH supplementation in men with erectile dysfunction currently, and studies demonstrating a role of GH and IGF-1 in development and progression of prostate cancer may further temper this possibility. However, recent studies, including ours, show potential and promise for new ways to enhance current treatment protocols that could improve quality of life in men with erectile dysfunction.
